Upregulation of GLS expression promotes glutamine depletion in tumor cells, leading to HIF-1α activation and IL-23 secretion by TAMs, which can inhibit the tumor-killing effect of cytotoxic lymphocytes (153). The gene discussed is GLS; the disease is neoplasm.